Cell-Easy and Toulouse University Hospital obtain IMPD approval for first-in-human clinical trial in systemic sclerosis, using promising allogeneic approach

EU regulatory approval to administer Adipose-derived mesenchymal Stem Cells (ASCs) in patients with ischemic digital ulcers marks key milestone for partners Toulouse, France, November 16, 2023 – Cell-Easy, a French Contract Development and Manufacturing Organization (CDMO) focused on advanced cell therapies, and the Toulouse University Hospital, today announce that they

Cell-Easy is pleased to welcome Mrs. Gisele Deblandre, formerly CSO at MaSTherCell, as Chief Scientific Officer.

Toulouse, France, September 21st of 2023 Cell-Easy, a specialized contract development and manufacturing organization (CDMO) in cell therapy, proudly announces the appointment of Mrs. Gisele Deblandre as the Chief Scientific Officer.   Over the years, Cell-Easy has recognized the challenges faced by biotechs in bridging the gap between early-stage projects

IUCT-Oncopole and Cell-Easy sign a MOU to accelerate cancer patient access to advanced cell-based therapy

TOULOUSE, FRANCE, June 22, 2023  IUCT-Oncopole and Cell-Easy SAS (Cell-Easy) announced today the signing of a Memorandum of Understanding to enhance their strategic collaborative relationship and open access to advanced cell-based therapies. This partnership aims to drive innovation in public health and improve access to promising new cancer therapies for patients.   By

Cell Easy appoints CDMO expert Dr. Sebastien Ribault as Independent Board Director, to accelerate its rapid growth.

  TOULOUSE, France _ April 10, 2023 Cell-Easy is a leading contract development and manufacturing organization (CDMO) with a strong foothold in Good Manufacturing Practice (GMP) manufacturing services for immune cells (T, NK cells) and adult stem cells (MSCs, iPSCs). Since 2020, the company keeps expanding into genetically modified cells